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In this thesis, we develop a system to study in vivo muscle function in a mouse 
model of Huntington’s disease that allows for the recording of muscle force by 
stimulating the motor nerves or the muscles directly after a nerve block. This allows us to 
distinguish between defects in the nerve, such as problems with vesicle release, and 
primary muscle defects, such as altered intracellular calcium homeostasis. We 
hypothesize that there are primary defects in R6/2 skeletal muscle that are separate from 
neurodegeneration or defects in the CNS. In this case, we should see defects in muscle 
force generation during nerve stimulation and direct muscle stimulation. If our hypothesis 
is shown to be correct, this work would highlight new targets to study for the treatment of 
HD. Peripheral treatments of skeletal muscle are a promising area for the treatment of 
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I. Specific Aims 
Specific Aim 1: To build a muscle force system capable of measuring in vivo muscle 
force from mice. The most challenging part of developing a muscle force system is 
designing a platform on which the mouse will be mounted. This platform will have to 
keep the hind limb stable so that the length of the muscle does not change during the 
muscle contractions. To achieve this, we will use computer automated design software to 
design the platform and then 3D print it. Printing the platform will give us the capability 
to make several prototypes easily and cheaply until the right design is achieved. Once 
constructed, we will assess the new setup by analyzing the force-frequency relationship 
and determining the twitch to tetanic ratio, which is the ratio of maximum twitch force to 
the maximum tetanic contraction. Obtaining this ratio will allow us to determine if there 
is any unwanted movement in the hind limb due to the design of the platform. 
Additionally, we will analyze the shape of the contractile responses to look for sharp 
changes in force that would indicate movement such as slipping of the suture.  
If there is no movement of the hind limb during force measurements, we should 





Specific Aim 2: To test for muscle weakness in R6/2 skeletal muscle in vivo using 
new muscle force system. To test for muscle weakness in R6/2 HD mice, we will expose 
the sciatic nerve and isolate the plantar flexor muscles (lateral gastrocnemius, medial 
gastrocnemius, plantaris, and soleus). Isometric muscle contractions will be recorded 
with a force transducer that is connected to the Achilles tendon with a suture. This 
approach was chosen so that we could record nerve-stimulated force and subsequently 
direct muscle-stimulated force after blocking neuromuscular transmission with α-
bungarotoxin. This will allow us to differentiate between defects of the nervous system 
and defects that are present in the muscle tissue itself. Recorded muscle force will be 
normalized to muscle weight to obtain specific force. This will allow us to compare HD 
to wild type mice as normalization will account for differences in force that are due to the 
smaller size of the HD muscles. Force-frequency experiments will be performed first 
with nerve stimulation, and again after blocking the nerve. First, we will compare WT 
records to HD to check for muscle weakness. We will also compare nerve vs muscle 
stimulated recordings to determine if any weakness we observe is a result of a nerve 
defect or a primary muscle defect.  
We hypothesize that HD mice have muscle weakness and therefore, we will observe 










Huntington’s disease (HD) is a genetic degenerative disease that presents with 
progressive cognitive and motor defects. The disease affects many areas of the brain, but 
most notably the areas known as the striatum (Vonsattel et al., 1985). The striatum is 
responsible for the control of smooth movement and a person’s mood (Bruce Koeppen 
and Bruce Stanton, 2017). All the muscles of the body are affected. Throughout the 
disease, the muscles will atrophy severely (She et al., 2011). Eventually, the affected 
person will lose control of voluntary movement and will be restricted to a chair. In all 
cases the disease is fatal. Unfortunately, there is currently no treatment that will prevent 
or even slow the progression of the disease. 
HD has been recognized as a disease as early as 1842. It was named after George 
Huntington, who gave his famous description of the disease titled, “On Chorea” in 1872. 
Huntington was the first to delineate the disease from other diseases of chorea. There 
were some other descriptions of HD before George Huntington that noted a hereditary 
form of chorea, notably by Charles Waters, Johan Christian Lund, and Groving Lyon 
(Bates et al., 2014). George Huntington was in a perfect position to make his 
observations of the disease. He had plenty of experience that was passed to him from his 
father and his grandfather who were both physicians that had seen HD patients over their 
years of practice (Bates et al., 2014). After Huntington, interest in the disease spread 
across America and Europe as well as some South American countries (Marsden, 1975).  
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Early research of HD was a slow and gradual process until it was better known. 
Several international organizations and lay groups, which were developed by family 
members of those with the disease, were instrumental in the progress of HD research over 
the past 40 years (Bates et al., 2014). The World Federation of Neurology Research 
Group on Huntington’s Disease was founded and first met in 1967 and has since evolved 
into the World Huntington’s Congress. This organization has held meetings every two 
years since its formation and has created a network of researchers around the world that 
has resulted in collaboration between researchers from a wide range of disciplines (Bates 
et al., 2014). Marjorie Guthrie, the wife of famous American folk singer Woody Guthrie 
who famously died from HD in 1967, devoted much of her time promoting HD and 
spreading awareness of the disease after Woody’s death (Bates et al., 2014).   
HD is inherited in an autosomal dominant fashion so that each child of an affected 
parent has a 50% chance of getting the disease (Myers, 2004). HD is an insidious disease. 
A person with the gene mutation will start life perfectly normal and then at around 
middle age will begin noticing subtle signs and symptoms. The age of onset varies widely 
and can be hard to assess due to subtle cognitive changes that can go unnoticed (Duyao et 
al., 1993). However, most patients develop noticeable motor symptoms around their 
forties and fifties (Myrianthopoulos, 1966; Ridley et al., 1991) such as chorea, rigidity, 
dystonia, and bradykinesia (Wells and Ashizawa, 2006).  
 HD is caused by a mutation in the huntingtin gene, specifically increased CAG 
trinucleotide repeats at the 5’ end of the gene (The Huntington’s Disease Collaborative 
Research Group, 1993). The gene codes for the huntingtin protein (Htt). It is located on 
the short arm of chromosome four at position 16.3. The gene consists of a polyQ domain 
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which codes for a stretch of glutamines in the protein. If the domain is expanded beyond 
36 glutamines, the carrier of the gene will develop HD (Myers, 2004). The expanded 
CAG repeat in the mutated huntingtin protein forms a polar zipper in the protein that 
results in protein aggregation (Perutz, 1995). Protein aggregates in many tissues are a 
hallmark of HD pathology (Arrasate and Finkbeiner, 2012; Hoffner and Djian, 2002; 
Scherzinger et al., 1997; Wanker, 2000). The age of onset is affected by the glutamine 
repeat number. There is an inverse correlation between the two, such that the more CAG 
repeats there are the earlier a person develops symptoms (Duyao et al., 1993). Once there 
are more than 50 glutamine repeats the carrier will develop the juvenile form of HD 
which has an earlier age of onset and death (van Dijk et al., 1986).   
Chorea is the main symptom of the disease and is the main sign used for 
diagnosis. Chorea consists of involuntary uncontrolled contraction of the muscles. This 
results in a clumsy-looking walk and slurred speech that can be mistaken for intoxication 
(Bates et al., 2014). Typically, in the early stages of HD, the muscles of the extremities 
will be affected. As the disease progresses the chorea spreads to more proximal muscles 
and those of the trunk of the body. When choreic movements begin they are usually so 
subtle they are unnoticed by others. Eventually, they get worse and it begins to make the 
affected individual clumsier and will make it more difficult to perform activities of daily 
living such as walking, speaking, chewing, and swallowing.  In later stages of the disease, 
chorea can be overshadowed by dystonia (random involuntary muscle contractions). 
Stress, anxiety, fatigue, and often caffeinated drinks can exacerbate chorea. Chorea 
eventually becomes so pronounced the affected individual can no longer work and will 
need family members or in-home caretakers to assist them. Due to disease onset 
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occurring in an individual’s prime career years, this situation puts significant stress on 
their families. Many families will fall down economic ladders as they lose income due to 
the affected individual’s inability to work, but also due to the expenses associated with 
the individual’s care. The leading cause of death in HD is aspiration pneumonia 
(Heemskerk and Roos, 2012). This is due to an inability to maintain the coordination of 
esophageal muscles and the epiglottis. When a person with HD swallows, food can get 
into the trachea and bacteria can infect the lungs. According to an analysis of 224 HD 
patients by Heemskerk and Roos, many of the cases where the cause of death could be 
identified died of aspiration pneumonia (Heemskerk and Roos, 2012). 
There is a wide range of cognitive and psychiatric changes associated with HD. 
Irritability is increased in HD. Patients can go through bouts where the smallest 
provocation can result in a sudden outburst of angry or even violent behavior. Most often 
this aggression is directed toward family or friends most directly involved in the patient’s 
care (Bates et al., 2014). Additionally, psychomotor slowing is a feature of HD and has 
been correlated to the CAG repeat number (Bamford et al., 1989; Snowden et al., 2002). 
Patients will take longer to perform the same tasks that they used to. Also, the perception 
of time becomes affected. These changes make it increasingly difficult to manage work 
and meet deadlines, especially for those with more demanding and higher stress careers.  
PERIPHERAL DEFECTS IN HUNTINGTON’S DISEASE 
The most overt and noticeable symptoms of HD are chorea and muscle wasting. 
Chorea being the main symptom used for diagnosis of the disease. It is not surprising that 
the bulk of the research on HD has been done with the aim of further understanding 
neuronal pathologies, especially with the significant psychological and behavioral 
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changes that accompany HD. It is a prevailing view that most of the peripheral defects 
found in tissues such as skeletal muscle are secondary to changes in the striatum. That is 
some changes, such as altered hormonal signaling from the hypothalamus, could alter 
physiology in other tissues outside of the CNS. Being a result of something that happened 
in the CNS, these pathologic events would be viewed as being secondary pathologies. 
However, it is now known that the huntingtin gene is expressed ubiquitously 
throughout the body (Hoogeveen et al., 1993; Li et al., 1993; Strong et al., 1993; Trottier 
et al., 1995) and major motor defects are a hallmark of the disease. Even though much of 
HD research has focused on the central nervous system (Lo and Hughes, 2011; Strand et 
al., 2005; The Huntington’s Disease Collaborative Research Group, 1993; Wells and 
Ashizawa, 2006), recent work has found many muscle defects that may help explain the 
motor symptoms of HD (Waters et al., 2013). Supporting that muscle defects may 
develop separately from neurodegeneration in humans, it has been observed that motor 
symptoms preceded the cognitive symptoms in a marathon runner (Kosinski et al., 2007) 
who was a carrier of the HD gene. A study of 960 patients showed that motor symptoms 
were the earliest disease symptom or sign in 56% of the participants (Marder et al., 
2000). 
As previously mentioned, the most noticeable issue with HD skeletal muscle is 
the fact that it is significantly smaller. HD patients are weaker and skeletal muscle 
wasting is often observed (Boesgaard et al., 2009; Ribchester et al., 2004), In the R6/2 
transgenic mouse model of HD, hind limb muscles are 40% lighter than WT muscles 
(Bondulich et al., 2017). It is not clear what the main cause of the loss in muscle mass is. 
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Some have hypothesized that it is due to metabolic changes or altered myocyte 
differentiation and apoptosis (Lodi et al., 2000; She et al., 2011). 
It has been previously shown, by our lab, that skeletal muscle is hyperexcitable in 
the R6/2 transgenic mouse model of HD, due to reduced resting currents through chloride 
channels (ClC-1) and inwardly rectifying potassium channels (Kir) in the muscle 
membrane (Waters et al., 2013). A recent publication examined neuromuscular 
transmission to assess the relationship between muscle and neuronal defects (Khedraki et 
al., 2017). Using voltage-clamp electrophysiology, Khedraki et al. found that 
spontaneous miniature endplate currents, nerve-evoked endplate currents, and the quantal 
content were reduced in R6/2 HD mice. 
Peripheral pathology in HD is not exclusive to skeletal muscle. Many if not all 
other cell types display pathologic changes in physiology, and this has been shown both 
in mouse models and HD patients. Mutant Htt inclusion bodies are a hallmark of striatal 
dysfunction. These inclusion bodies have now been found in peripheral tissue as well 
(Orth et al., 2003; Trottier et al., 1995; van der Burg et al., 2009). Mutated Htt is known 
to disrupt gene expression (Chaturvedi et al., 2009; Luthi-Carter et al., 2002; Strand et al., 
2005), which could lead to widespread dysfunction in peripheral tissues. 
Cardiac tissue has significant defects in both humans and mice. Reduced cardiac 
output and decreased myocardial thickness have been shown (Mihm et al., 2007; Pattison 
et al., 2008), Cardiac failure occurs in 30% of patients with HD (Lanska et al., 1988). 
There is also very high expression of Htt in the testes (Strong et al., 1993). This results in 
decreased concentrations of testosterone and correlates with a worsening of the disease 
overall (Markianos et al., 2005; Saleh et al., 2009). Additionally, there is a significant 
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disruption of function in the digestive tract. In patients and mice, there is a loss of 
ghrelin-producing neurons which regulate the sensation of hunger (van der Burg et al., 
2008). Decreased insulin production also occurs which leads to glucose intolerance 
(Björkqvist et al., 2005; Duan et al., 2003; Farrer, 1985; Hurlbert et al., 1999; Josefsen et 
al., 2008; Podolsky et al., 1972; Podolsky and Leopold, 1977). Finally, mitochondrial 
dysfunction is known in several tissues, including skeletal muscle, and could underly 
some of the weight loss in HD patients (Arenas et al., 1998; Ciammola et al., 2006; 
Turner et al., 2007).   
A growing body of evidence is suggesting that some of these peripheral defects 
are not secondary to defects in the striatum. Testicular degradation develops before 
reductions in testosterone or gonadotropin-releasing hormone (Van Raams donk et al., 
2007). Gonadotropin-releasing hormone is produced by the hypothalamus. If this were a 
secondary pathology one would expect to see a reduction in gonadotropin-releasing 
hormone before dysfunction in the testis. Additionally, concentrations of the luteinizing 
hormone do not correlate to reductions in testosterone (Markianos et al., 2005). Some 
studies have even shown that these peripheral defects can contribute to pathology in the 
brain (Chiang et al., 2007; Martin et al., 2009). 
As can be seen HD is a complex disease and many tissues and body systems are 
impacted.  To fully understand this disease, it is important to assess the peripheral defects 
as they could be novel targets for the treatment of the disease. Our lab is focused on the 
motor symptoms of HD. As has been discussed, the motor symptoms are debilitating for 
patients and are the main reason that their lives are unraveled and are ultimately a major 
cause of death. The main causes of death in HD are aspiration pneumonia and choking 
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(Lanska et al., 1988; Sørensen and Fenger, 1992) due to the dysfunction of the muscles 
involved in swallowing and chewing. In this project, we studied muscle function in the 
R6/2 mouse model of HD by performing in vivo measurements of muscle force. In the 
following section, we will cover the physiology responsible for muscle contraction at the 
cellular level.  
SKELETAL MUSCLE PHYSIOLOGY 
Skeletal muscle in the body is responsible for generating the force required to 
perform work such as moving, breathing, swallowing, talking, facial expression, and so 
on. To perform a movement, such as picking up a glass of water, the muscle must receive 
an impulse from the nerves that innervate it. The idea that nerves are responsible for 
propagating the signal from the brain to the muscles dates back as far as the 2nd century 
(Drukarch et al., 2018). However, the “modern” view of nerve conduction known as the 
“neuron doctrine” began to be developed in the late 19th century. Luigi Galvani in 1791 
made an accidental discovery that electric current can excite nerves and cause muscle 
contraction in frog legs (Galvani, 1791). In subsequent experiments, he demonstrated that 
there is an electrical force in animal tissue that is responsible for the contraction of 
muscles. Using a galvanometer Emil du Bois-Raymond measured the first “action 
potential” (AP) in frog nerves by noticing a negative voltage deflection when the nerve 
was excited with respect to a region at rest (Du Bois-Reymond, 1884). 
As with many discoveries, the electrochemical basis of nerve conduction and 
muscle contraction was dependent on incremental advancements of technology and 
experimental techniques. The development of the light microscope and advancements in 
histological preparation allowed for early neuroanatomists to visualize neurons in greater 
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detail. Importantly, Ramón y Cajal, now known as “the father of modern neuroscience”, 
utilized staining techniques, developed by Camillo Golgi, that allowed him to make 
marvelous depictions of nerves in the 1880s that included the cell body, dendrites, and 
axons in stunning detail. His work made it possible for Sherrington to develop the 
concept of the synapse in 1897 (Smith, 1996). The prevailing theory at the time was that 
nerves formed an interconnected network instead of being discrete separated cells 
(Drukarch et al., 2018).  
In 1938, John Young performed important experiments showing that the giant 
axons of the squid were in fact motor neurons (Young, 1938). Their stimulation cause 
contraction of the muscles of the mantle of the squid. These giant axons were perfect at 
the time to allow for electrical recordings to study the function of these nerves. This was 
the beginning of the field of electrophysiology. The recording electrodes at the time were 
too big for intracellular recordings in most other cells. Much of the pioneering work on 
the electrical properties of nerves were done in these giant axons. Hodgkin and Huxley 
saw the benefit of the giant axons and for the first-time recorded APs from the inside of 
the nerve in 1939 (Hodgkin and Huxley, 1939). This work led to the formulation of 
Hodgkin and Huxley’s current equation, which allowed for the quantitative assessment of 
nerve properties under various conditions (Hodgkin and Huxley, 1952a). Hodgkin and 
Huxley were ultimately awarded the Nobel Prize for this work in 1963. 
The aforementioned Andrew Huxley as well as Hugh Huxley showed 
coincidently that the actin and myosin proteins that make up a muscle fiber slide across 
one another to cause muscle shortening (Huxley and Niedergerke, 1954; Huxley and 
Hanson, 1954). This work paved the way for the sliding filament theory of muscle 
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contraction. At the time, the prevailing view was that muscle contracted by the folding or 
coiling of various proteins within the muscle fiber.  
It was not until the development of the electron microscope that the complete 
picture of muscle contraction was resolved. Electron microscopy in conjunction with x-
ray crystallography was used to decipher the 3D structures of the various protein 
channels in the muscle membrane. Once these structures were determined their various 
functions and gating mechanisms were determined. In the following paragraphs, we will 
discuss the physiological events that take place to cause a muscle contraction starting 
with the generation of an AP and ending with the process known as excitation-
contraction (EC) coupling. We will also discuss the various proteins involved in the 
process and how they work to ultimately cause muscle contraction and then relaxation.  
 The electrical impulse that travels along the axon of a nerve is known as an AP 
(Hodgkin and Huxley, 1952a). All cells in the body have a membrane composed of a 
phospholipid bilayer (Gorter and Grendel, 1925). This membrane is impermeable to 
charged particles called ions (Na+, K+, and Ca2+ being the important ones for the process 
being discussed here). The ions are held at varying concentrations inside and outside the 
cell and create an electrochemical gradient (Bernstein, 1912) that can be harnessed to 
perform work within the cell. Also present in the cell membrane are various proteins that 
act as channels for the ions allowing them to move from one side of the membrane to the 
other down their electrochemical gradient (Danielli and Davson, 1935; Neher and 
Sakmann, 1976). The AP that travels down the motor nerve causes a depolarization that 
is due to the opening of Na+ channels on the membrane (Overton, 1902). The Na+ 
channels are voltage sensitive meaning that a change in the voltage difference between 
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the voltage on the outside of the membrane and the inside in the vicinity of that channel 
will cause the channel to open and allow Na+ to flow into the cell. This makes the 
membrane potential more positive and the other Na+ channels in the vicinity will also 
open. This is what allows the AP to propagate down the axon to the nerve terminal. The 
AP will originate in nerve bundles located in the ventral horn of the spinal cord (Hong 
and Etherington, 2011). The impulse travels down the axons until it reaches the nerve 
terminal which forms a synapse with the muscle fiber membrane known as the 
neuromuscular junction (NMJ) (Kühne and von Voit, 1886).  
Once the impulse reaches the NMJ, voltage-sensitive Ca2+ channels open in 
response to the AP and cause vesicles in the nerve terminal containing acetylcholine 
(ACh) to fuse with the membrane releasing ACh into the interstitial fluid(Couteaux and 
Pécot-Dechavassine, 1970; Dale, 1914; Katz and Miledi, 1967). The membrane on the 
muscle fiber directly below the nerve terminal is known as the synaptic cleft. This area of 
the membrane has many nicotinic ACh receptors that bind ACh. The binding of ACh to 
the receptor causes Na+ to enter the muscle fiber and depolarize the muscle membrane 
(Fatt and Katz, 1951; Neher and Sakmann, 1976b). This causes APs to propagate down 
the muscle fibers of the muscle starting a cascade of events that eventually leads to 
muscle contraction. This whole process is known as excitation-contraction (EC) coupling. 
To fully understand this process, we must first look at the organization of muscle starting 
at the level of the whole muscle and going all the way down to the individual muscle cell.  
Muscles are made up of many small fibers that can stretch the length of an entire 
muscle. The muscle fiber is a single muscle cell. The muscle cell or myocyte is made up 
of repeating contractile units called a sarcomere (Bowman and Todd, 1840; 
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Leeuwenhoek, 1710). A sarcomere is a meshwork of different proteins that can work 
together to contract in response to the muscle AP. The sarcomere is made up of actin and 
myosin proteins which are known as thin and thick filaments, respectively as well as 
some other proteins that work as the framework of the sarcomere (Hanson and Huxley, 
1953; Huxley and Hanson, 1954). Thick and thin filaments are known as myofibrils. 
Actin is anchored to the Z-line of the sarcomere by a protein called titan (Kuroda and 
Maruyama, 1976; Wang et al., 1979). The Z-line is the border of the sarcomere and there 
is a Z-line on each end of the sarcomere. Many parallel actin filaments stretch from each 
Z-line toward the middle of the sarcomere. In between each actin filament are the thick 
filaments. They start at the midline of the sarcomere and stretch toward the Z-line. This 
organization of myofilaments is what gives skeletal muscle its striated appearance. The 
actin filament is a braided fiber of actin molecules (Holmes et al., 1990). The fiber has 
many binding sites for myosin. These sites, in the resting state, are covered up by another 
protein called tropomyosin. This protein has binding sites for Ca2+ so that when 
intracellular Ca2+ ([Ca2+]i) rises Ca2+ binds to tropomyosin and causes a conformational 
change in the protein so that it uncovers the binding sites for myosin (Spudich et al., 
1972; von der Ecken et al., 2015). This will allow myosin to bind to actin so that cross-
bridge cycling can begin which will lead to muscle contraction.  
Along the muscle fiber membrane, regions of the surface membrane fold inward 
toward the fiber interior to form narrow tubes. The system is known as the transverse 
tubular (t-tubular) system and is continuous with the surface membrane (Huxley and 
Taylor, 1958; Porter and Palade, 1957). The t-tubules are essential for coordinated 
sarcomere shortening across the entire fiber. They allow for the AP to propagate into the 
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center of the fiber so that the entire muscle fiber receives the signal to contract. Also, the 
t-tubules contain the voltage-sensitive dihydropyridine receptors that are mechanically 
coupled to L-type Ca2+ channels (ryanodine receptors) on the membrane of the 
sarcoplasmic reticulum (Curtis and Catterall, 1984; Inui et al., 1987). The sarcoplasmic 
reticulum is the reservoir for Ca2+ in the myocyte. Once the AP reaches the 
dihydropyridine receptors they undergo a conformational change that causes the 
ryanodine receptors to open and allow for the release of Ca2+ into the cytoplasm of the 
cell (Endo, 2007; Weber and Herz, 1968). This rise in [Ca2+]i ultimately leads to muscle 
contraction. The t-tubules are lined up over the Z-lines of the sarcomere. This ensures 
that Ca2+ is released in the vicinity of tropomyosin so that the Ca2+ will bind and 
uncover the binding sites for myosin.  
Myosin has a globular head and a tail domain. (Rayment et al., 1993). The head of 
the myosin protein contains an ATPase. This enzyme will hydrolyze ATP to ADP and 
phosphate (Lymn and Taylor, 1971). This chemical reaction is what releases the energy 
necessary to perform the mechanical work required for the shortening of the sarcomere. 
During contraction, this process is happening repeatedly so that all the myosin heads are 
“walking” along the actin filament toward the Z-lines. This is known as the sliding 
filament theory (Finer et al., 1994; Gordon et al., 1966; Huxley and Niedergerke, 1954; 
Huxley and Hanson, 1954; Toyoshima et al., 1987). This process will continue until no 
more APs come from the motor nerve. At this point [Ca2+]i will begin to be pumped back 
into the SR via the SERCA pump (Toyoshima et al., 2000). Thus, [Ca2+]i will decrease to 
resting myoplasmic levels. Ca2+ will fall off tropomyosin causing the binding sites for 
myosin to be covered. ATP binding to the myosin ATPase causes the head of myosin to 
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unbind from actin. This causes relaxation of the muscle and the return to resting muscle 
length and tension. 
MUSCLE FORCE EXPERIMENTS  
Given the known defects at the neuromuscular junction and in channels on the 
muscle fiber membrane of R6/2 mice, we hypothesize that muscle function is affected by 
these defects and will, therefore, be weaker than their wild type littermates. To test this 
hypothesis, we measured muscle force in vivo in the R6/2 mouse model of HD. It has 
been shown using ex vivo techniques that HD muscle is 75% weaker than WT muscle 
(Hering et al., 2006). In this study muscle force from extensor digitorum longus (EDL) 
and soleus muscles (hindlimb dorsiflexor and plantar flexor muscles) was measured using 
ex vivo techniques. These experiments were performed at room temperature. Our 
experiments were be performed in vivo at physiological temperatures, which could result 
in significantly different muscle force as was previously reported. Muscle force is known 
to be reduced at room temperature (Caremani et al., 2019), and it is unknown if this 
temperature effect will impact muscle force differently between WT and HD.  
Gillian Bates, part of the team that developed the R6/2 mouse line, and a team of 
researchers tested muscle force in R6/2 mice in 2015 (Mielcarek et al., 2015). They also 
showed that muscle force is reduced in HD mice when compared to WT, but only by 
25%. They measured muscle force in both the tibialis anterior (TA) and EDL using in 
vivo techniques. In this study, raw muscle force was given in grams of force. The muscle 
force was not normalized to muscle size in any way.  As one would expect a smaller 
muscle should produce less force than a larger muscle. So, the question at hand is 
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whether HD is truly weaker than WT once this reduction in muscle mass has been 
accounted for.   
As Hering et al. and Mielcarek et al. have shown differing results, we thought it 
was worthwhile to revisit muscle force in the R6/2 mice. Both studies used hind limb 
muscles, but they used only single muscles in their recordings. We plan to use the whole 
group of plantar flexor muscles that attach to the Achilles tendon. Like the Mielcarek 
study, we performed in vivo measurements while the mouse is anesthetized. We also 
recorded muscle force in response to nerve stimulation and direct muscle stimulation 
after application of α-bungarotoxin (BTX) to assess nerve and muscle function directly. 
Finally, after muscle force recordings we muscle weight was collected so that the force 
records could be normalized to muscle weight to account for differences in muscle size 
between HD and WT.  
To obtain isometric muscle force recordings in vivo, we first built a system to do 
so. The in vivo system was built using a combination of commercially available 
equipment as well as a custom platform to which the mouse can be secured during the 
experiments. It was key to secure the hind limb of the mouse to eliminate any movement 
during muscle contractions. Any movement during contractions will result in unstable 
recordings and will prevent the successful detection of peak force during twitch and 
tetanic contractions. It will also make it difficult to maintain optimal length during the 
experiment. We utilized both computer automated design software and fused deposition 




III. MUSCLE FORCE SYSTEM DEVELOPMENT 
EXPERIMENTAL GOALS AND CONSIDERATIONS 
As previously stated, specific aim 1 of this this was to design and build a muscle 
force system to take isometric force measurements from R6/2 hind limb muscles in vivo. 
In this section, we will cover the important factors that were considered before designing 
the system to achieve this goal. In the following section, the actual components of the 
muscle force system will be described as well as the design process. Additionally, some 
preliminary data from the various prototypes will be shown and discussed.   
The choice of in vivo recordings was made to study muscle force in conditions 
that are as close to physiological as possible. Additionally, we wanted to be able to 
perform nerve as well as direct muscle stimulated muscle contractions after applying 
BTX. This technique is important to be able to identify problems related to 
neurotransmission in the nerve terminal and synaptic cleft. Additionally, comparing 
direct muscle stimulated force with nerve stimulated force allows for the identification of 
altered muscle properties directly that are independent of nerve function.  
The muscles that we chose to record from are the plantar flexor muscles, which 
include the lateral and medial gastrocnemius, plantaris, and soleus. These muscles are 
part of a whole muscle group that attaches to the calcaneal bone by the Achilles tendon. 
This prep has the advantage of studying the muscles as a functional group as they are 
used during locomotion. As stated before, the aspect of performing these experiments in 
vivo means that the muscle was maintained at 37 ˚C as it would be in the intact animal. 
There are known differences in cellular physiology at room temperature vs. physiological 
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temperature. Performing experiments at room temperature will slow down enzyme 
kinetics and could reduce things like myosin light chain phosphorylation which will alter 
muscle function. We wanted to minimize these effects in our prep. Finally, in vivo 
conditions maintain normal blood perfusion to the muscles as the muscle remains 
connected to its blood vessels. In ex vivo experiments the muscles need to be bathed in a 
physiological buffer solution. In the prep discussed here, this is unnecessary. 
We planned to perform recordings of isometric muscle contractions from the 
plantar flexor muscles. To get accurate results of peak muscle force we must keep the 
muscle fixed in place and assure there are no movements in either the hind limb or mouse 
during the muscle contraction. To achieve this, we went through a lot of trial and error in 
our methods of securing the mouse and the hind limb to the platform on which the mouse 
is mounted. We also needed a way to achieve the optimal length of the muscles we were 
recording from. To do this we mounted the mouse platform to a micromanipulator that 
can move the platform so that the muscle is either stretched or relaxed when attached to 
the lever of the force transducer. Peak muscle force at a given frequency can only be 
achieved when the muscle is at an optimal length. This is the resting tension of the 
muscle in which the sarcomeres are arranged in such a way that the most cross-bridge 
cycling can occur while still having room for the sarcomere to shorten. If during a 
contraction the mouse or hind limb moves toward the force transducer the length of the 
muscle will no longer be optimal, and you will no longer be recording the true peak force 
of a contraction. Additionally, you will see a drop in the baseline, or resting tension, in 
between recordings.  
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 In early experiments we noticed that, not only would the mouse move, but the 
suture securing the tendon to the lever of the force transducer can also slip. This causes 
the same issues mentioned in the previous paragraph. However, instead of the limb 
moving toward the force transducer during the muscle contraction, you are now unable to 
maintain the proper tension on the muscle and therefore the muscle is no longer at 
optimal length for the following recordings. The final issue regarding muscle tension and 
the optimal length is that the suture must be strong enough to oppose the force generated 
during peak muscle force during tetanic contractions. If the suture is the wrong material 
or is too small of a gauge it will snap during the strongest contractions. These 
considerations make the choice of suture and the knots that are used very important for 
the accurate assessment of peak muscle force during stimulated contractions.  
Our goal was to design a custom platform that is optimized with these 
considerations in mind to be used in conjunction with commercially available recording 
hardware and software. Before the development of this system, our lab specialized in 
skeletal muscle electrophysiology. For these experiments, we used a digitizer from 
Molecular Devices as well as their suite of recording and analysis software called 
pClamp. Due to our familiarity and expertise in setting up and using this equipment we 
decided to use Molecular Device’s digitizer and software for the muscle force system.  
The only other recording equipment we needed to add was the force measurement 
hardware. To record muscle force, we needed a force transducer. Most force transducers 
measure muscle force using an analog signal such as voltage. This signal must be able to 
be sent to the amplifier and then to the digitizer to be sent to the computer. Additionally, 
we wanted a force transducer that is capable of recording isometric, isotonic, as well as 
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eccentric muscle force. Although we are only concerned with isometric force 
measurements for this thesis, we wanted the ability to perform other experiments later. 
Finally, to complete the system we needed a way to deliver anesthesia to the mice. 
It is very important to be able to accurately control the sedation of the mouse during these 
experiments. These experiments can be well over an hour in length, especially with more 
complex stimulation protocols. Therefore, we needed a system that can keep a mouse 
stable under anesthesia for the duration of the experiment. It is also very important to 
maintain the body temperature of the mouse while it is anesthetized. The core 
temperature of a mouse is 37 ˚C. We needed our system to be able to measure and 
maintain the body temperature simultaneously with a temperature probe and a heat 
source.  
IN VIVO MUSCLE FORCE SYSTEM OVERVIEW 
The muscle force system can be broken down into five main parts: life support, 
the surgical platform, the muscle force platform, the data acquisition hardware, and the 
peripherals. A diagram of the system's main components is shown in figure 1 and each 
part will be broken down and described in this section.  
Arguably, one of the most important parts of this system is life support. As these 
experiments were performed in vivo, the animals had to be maintained in a sedated state 
during the entire experiment. Nothing is more important than the welfare of the animal 
during these experiments. Anesthesia must be delivered in a way so that we can perform 
our experiments and cause no harm or suffering to the animal. It has been well 
established how to safely administer anesthesia to animals during experimentation (Kohn, 
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1997) and all the experiments in this thesis were performed while strictly following 
procedures and protocols approved by the Wright State IACUC committee. The 
anesthesia system that was ultimately chosen was the Somnosuite low flow anesthesia 
machine from Kent Scientific. This system checks all the major boxes that we need with 
some additional features.  
The Somnosuite allows you to deliver isoflurane in a controlled way as well as to 
monitor and maintain body temperature with a built-in temperature probe and a heating 
pad. The system has a digital screen that allows you to monitor the isoflurane flow rate 
and concentration. To deliver isoflurane we are using 99% O2 as opposed to room air, 
which can also be used with the SomnoSuite. We found that 99% O2 worked better to 
maintain the HD mice during longer experiments.  The SomnoSuite can also send the 
temperature signal to our digitizer so that we can have a recording of animal temp during 
our entire experiment. The machine includes a heating pad that can automatically 
regulate body temp when used with the temperature probe. However, we only use the 
heating pad to preheat the surgical and force platforms. As you will see later the built-in 
heating pad is not able to be used during the surgery and force measurements because we 
place pins through the paws into the platforms. To solve this issue used a lamp with a 
ceramic heat bulb on a boom arm to provide heat to the mouse while anesthetized. The 
boom arm allows the heat lamp to be moved from the surgical platform to the muscle 
force platform as needed. To maintain 37 °C the core temperature of the mouse is 






Figure 1: In Vivo Force System Diagram The in vivo muscle force system functions through the 
coordination of five smaller systems; life support, surgical platform, force platform, peripherals, and 
acquisition hardware. Included is a list of the unique components of each system.  The arrows highlight 
how each of the systems function together to obtain in vivo force data. 
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One of the great features of the Somnosuite is that it was designed specifically for 
small animals. The alternative options, such as traditional veterinary vaporizers are made 
to be used with a wide range of animals with a wide range of sizes. This means that for 
small animals like mice, conventional vaporizers are very inefficient and put out more 
gas than the lungs of the mouse will ever utilize. This is where the low flow aspect of the 
Somnosuite is very advantageous. The system drastically reduces costs for isoflurane and 
oxygen as much less is used during a given experiment. 
A diagram of the anesthesia machine is shown in figure 2. The SomnoSuite uses a 
syringe that is placed into a clamp. The syringe is filled with isoflurane which is the 
anesthetic that we are using. The plunger of the syringe is depressed automatically by a 
block that rides along a lead screw. The lead screw is attached to a motor so that it turns 
at a given rate determined by the isoflurane concentration setting. The isoflurane is 
pushed through a vaporizer block where it mixes with the O2 which is the carrier for the 
isoflurane molecules. The gas is then sent to the lines that are used for inspiration. The 
mouse breaths in the gas, whether it is in the induction chamber or through the face mask, 
and then the exhaled air returns to the machine through the expiration lines. The waste 
gas is sent through a carbon scrubber that filters vapors that are carcinogenic to the 
experimenter.  
The muscle force platform is where we spent most of our time and energy in the 
design stage of this project. This is the only component that had to be made custom for 
our experimental purposes. There are some commercially available solutions from 
various companies, but they are cost-prohibitive and are not tailored to our exact needs. 




Figure 2: Anesthesia System The anesthesia machine being used in our muscle force system is the 
SomnoSuite from Kent Scientific. It is a low flow anesthesia system that delivers precise inhalant 
anesthetics at a rate optimized for small animals like mice. Isoflurane is pumped automatically from a 
syringe into the vaporizer block and then vaporized anesthetic is sent through the inspiratory tubes (blue 
arrows). Exhaled gas is sent back to the machine through the expiratory tubes (red arrows). The gas is 
then sent out the back of the machine and through a carbon scrubber to get rid of the toxic by-products 
of exhaled isoflurane. The system also features an induction chamber for anesthetizing the animal. It 
also has a heating pad and temperature probe for monitoring core body temp during experiments. 
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handmade prototype and ultimately went through three variations of the platform until we 
developed the fourth and final version of the platform. The platform was aptly named the 
Achilles after the tendon from which we are recording muscle force.  The Achilles 
platform and its development will be described in detail in the next section.  
The data acquisition hardware is the next key component of the muscle force system. The 
two main pieces of equipment are the muscle force transducer controller and digitizer. 
Aurora Scientific produces a dual-mode lever controller. It can simultaneously record 
muscle force and control muscle length. This gives us the ability to perform eccentric and 
isotonic force measurements. The 305C is a two-channel controller so we can also use 
two different force transducers with different force ranges without changing our setup. 
We chose this option to be able to have an in vivo system as well as ex vivo. The force 
transducers are very precise micro stepper motors. They have a variable resistor on the 
shaft of the motor so that force can be measured in the form of a voltage signal. A small 
lever is attached to the motor shaft. The tendon of the muscle that is being recorded from 
pulls on the lever and sends an increasing voltage signal to the digitizer. The digitizer 
then converts the voltage signal into a digital signal that is sent to the computer. This is 
ultimately shown in the acquisition software as a force recording.  
The digitizer we selected is the Digidata 1550B from Molecular Devices. It has an 
array of digital inputs and outputs as well as analog inputs and outputs. These allow us to 
integrate peripheral devices, such as stimulators or temperature controllers, into the 
system. These can also be triggered with our computer using the digital outputs and can 
be automated when used with the pClamp software. The recorded signals such as the 
force measured by the force transducer are sent to the analog inputs of the digitizer. The 
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1550B has a total of ten inputs and outputs, both analog and digital, which gives us many 
options for adding other peripheral hardware in the future.  
The only peripheral hardware essential for this project is the pulse generator that 
we use to stimulate the nerve. The pulse generator that we chose is the S-900 from 
Dagan. This pulse generator has many options for creating pulse trains, but we chose it 
for its ability to be triggered with the computer. To create the various trains for the force-
frequency experiments, we have set the simulator to generate a 1 ms pulse and put it on 
trigger mode. When the generator receives a 5 V triggering pulse from one of the digital 
outputs of our digitizer it will fire a pulse. In the software, we can send out complex 
trains of triggering events so that we can stimulate the nerve at any frequency for any 
amount of time.  
Our system also utilizes a temperature controller so that we can perform ex vivo 
experiments at a physiological temperature. Additionally, we added a differential 
amplifier that can record muscle compound APs during muscle contractions. This gives 
us the ability to generate EMG recordings during our in vivo contraction experiments. 
The numerous amounts of inputs and outputs on the digitizer gives us plenty of room for 
expansion in the future.  
THE ACHILLES PLATFORM 
Now that we have a general overview of the muscle force system and its various 
components, we will discuss the development of the Achilles platform. We developed 
four versions of the platform in total. We made incremental improvements with each 
version. Here, this process will be shown step by step with some preliminary data and the 
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various features of the final version of the platform will be highlighted in the following 
section. 
The first version of the Achilles platform was hand made. We started with a 
simple breadboard and a micromanipulator from Thorlabs (XR25C). The plan for 
recording muscle force was to have the mouse in the prone position and the caudal end of 
the mouse towards the force transducer. The plantar flexor muscles would be exposed, 
and the Achilles tendon attached to the lever of the transducer with a suture (6-0 braided 
silk suture was used with a modified Miller’s knot). To fix the mouse to the platform we 
chose to use Sylgard (Sylgard 184, Dow Corning, Michigan, US) a silicone elastomer 
that comes as a two-part kit that you mix and let cure. Once cured it is a pretty solid 
elastomer with a little bit of give. To keep the mouse in place its limbs can be secured to 
the Sylgard by placing pins through the paws of the mouse into the Sylgard. The platform 
would need a cavity in which the Sylgard could be poured and held during the curing 
process. We decided to use a culture flask which had two advantages.  The first was that 
we could pour the Sylgard into the flask and let it cure. The flask was mounted to the 
breadboard horizontally and was cut in half so that the mouse could lay on top of a bed of 
Sylgard. Secondly, the mouth of the flask gave us a surface onto which we could pin the 
foot while maintaining its natural position at a 90° angle to the tibia. 
Using Achilles I, we were able to collect some preliminary force-frequency data. 
However, this data had some key issues that needed to be worked out. First, it was clear 
that the hindlimb of the mouse needed to be secured with more than just a pin into the 
Sylgard through the paw. There was some clear movement that could be detected in our 




Figure 3: Preliminary Force Data Artifacts Achilles I produced force data that was unreliable. 
Common issues included slippage of the suture securing the tendon to the force transducer. The 
record shown in panel A is an extreme case of this. The slipping of the suture can be seen by the 
sudden loss of force in the middle of the trace. Black arrows are pointing to breathing artifacts due 
to excess movement in the hindlimb.  Many of the traces contained significant shifts in the baseline 
as can be seen in A and B above.  
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limb not being properly secured (Figure 3A). Additionally, after a contraction, especially 
those near the maximum, a baseline shift could be detected by a reduction in resting 
tension at the beginning of the following recording (Figure 3A & B). This is unacceptable 
as subsequent recordings would no longer be made at the optimal length of the muscles. 
To prevent this movement, we came up with a couple of solutions to fix the leg in place 
during recordings.  
The first solution that we tried was to use a staple to pin the upper leg to the 
Sylgard of the platform (Figure 4A). This worked at first, but as we learned it also created 
two new problems. The first problem that was noticed was that overtime the Sylgard 
began to wear out from being punctured repeatedly by the pin. This makes it porous and 
allows the staple to back out during contractions. This renders the staple ineffective for 
limiting unwanted movement during muscle contractions. To address this, we came up 
with a way to pin the leg down in the same manner as the staple while not depending on 
Figure 4: Hind Limb Immobilization Achilles I & II Originally staples over the femur and ankle were pinned 
into the Sylgard of the platform (A) to secure the hind limb. Later we developed a system utilizing metal 
straps to secure the ankle and foot to the platform to immobilize the leg during recordings (B).  
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the Sylgard to keep it in place. We developed a rail system in which we could clamp a 
rod that had a staple on the end. This rod can then be lowered in place and clamped down 
so it will not move during contractions. Additionally, we made some metal straps that 
could be used to secure the foot and ankle (Figure 4B). These improvements were 
integrated into the second and third versions of the platform, Achilles II and III.   
Achilles II was also hand made. We used a micropipette tip container that we 
trimmed down to size. Additionally, we added holes so that we could place threaded 
inserts so that we could screw our new straps into place (Figure 5A). This prototype 
provided the framework for us to make what we thought at the time would be the final 
version of the platform. Achilles III was 3D modeled in CAD software and then printed 
using a 3D printer (Figure 5B). This will be discussed in more detail in the paragraphs to 
follow while discussing the details of Achilles IV. The rail system was made utilizing 
some basic metal rods as well as some x blocks (UX-6-6) from Thor Labs. The metal 
rods have tapped holes on the end so they can be secured to the breadboard that the 
Figure 5: Achilles II & III Achilles II was developed to add the metal straps that are used to secure the foot 
and ankle of the mouse. Additionally, the rails system and leg clamp rod were added (A). Inserts and 
holes for fasteners were also added. Finally, epoxy was poured into the bottom before adding Sylgard to 
reduce the amount of Sylgard being used. Achilles II was eventually streamlined and redesigned in CAD 
to be 3D printed. The 3D printed Achilles III is shown above (B). 
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platform is mounted to. The x blocks allow us to position the rod precisely over the leg so 
it can be clamped down. The combination of the new rod system and metal straps 
drastically reduced the unwanted movements during muscle contractions. Breathing 
artifacts were essentially gone and there were no more shifts in baseline between 
recordings.  
As mentioned before the stapling technique presented an additional problem. 
When we decided to use the staple, we failed to consider the underlying anatomy of the 
upper leg. We were placing the staple over the femur. Coincidently, the femoral artery 
runs along the femur. It was not until we started clamping down the leg with the rod that 
we noticed that blood flow to the lower leg and thus to the plantar flexor muscles was 
being constricted. The original staple was backing out and was therefore not constricting 
blood flow enough for us to notice. However, the rod being clamped was so effective that 
when the leg pushed against it during contractions it was able to cut off the blood flow.  
With limited blood getting to the plantar flexor muscles, we noticed force decline 
when performing repeated stimulation. At this point, we went back to the drawing board 
to address this issue. The first and obvious issue was that the end of the rod was pushing 
down on the tissue of the thigh with too much force. To ensure this was no longer an 
issue we wanted to abandon clamping the leg directly secure it in place. Instead, we 
decided to brace the entire rear end of the mouse. When the muscle pulls on the lever 
during a contraction it also pulls on the leg. This causes the whole body of the mouse to 
move toward the force transducer. Therefore, we thought that if we could limit the body 
movement, we would eliminate the movement of the upper leg without having to clamp it 
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directly. So instead of using one rod clamped at the top, we used two. One was placed on 
the hip area and the other was placed on the inner thigh and groin area (Figure 6).  
The next thing that was done to eliminate the restriction of blood flow to the 
plantar flexor muscles was to change the design of the platform itself. Blood flow is 
maintained when the leg is kept in a more natural position. When a mouse is in a prone 
position the leg is not stretched out flat as it has been in the first three versions of the 
Figure 6: Hind Limb Support Rods and Rail System The hindlimb needed to be secured near the hip as well 
as near the ankle. The image above shows the rails system we developed to properly secure the caudal 
end of the mouse and thus the upper leg. Two rods are fixed to a rail system over the platform. The rods 
can be moved precisely along the x and y-axis of the platform to properly position them at the hip and 
are secured in place using thumbscrews so that they do not move at all during experiments. Since we 
were no longer dependent on the Sylgard for securing the hind limb we did not have to worry about 
baseline shifts in force records after repeated use of the platform. 
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Achilles platform. The lateral and medial condyles of the femur protrude enough to limit 
blood flow through the arteries supplying the plantar flexor muscles when the leg is 
clamped flat. The next modifications to the platform were made to accommodate a 
natural leg position with the leg being slightly bent. To achieve this, we added a second 
platform on top of the original platform that is shorter than the base. The front of the 
upper platform has an angle on its edge so that the upper leg can rest on it. The shin of 
the leg then rests on a bed of Sylgard. Additionally, Achilles IV only has Sylgard in the 
areas it is needed as opposed to the entire platform. There is an area for the paws to be 
pinned down and an area for the lower leg to rest on. Finally, we made the upper platform 
adjustable to accommodate legs of various sizes.  
Figure 7: Achilles IV In the final version of the force platform an upper platform was added for two 
reasons. The fist was to raise the body of the mouse higher than the lower hind limb to maintain the 
natural leg position as well as to increase blood flow. A beveled edge was added to support the upper 
leg and maintain a bend in the leg while the mouse was in the prone position. The new platform was 
kept as a separate part to allow for the top to be adjusted to accommodate the various leg sizes of 
different mice (A). Also, goal with the final design was to reduce the amount of Sylgard used. Instead of 
one large cavity with Sylgard, there are now two small cavities only where the Sylgard is necessary. The 
cavity on the upper platform is for pinning the paws. The lower cavity is to for the lower limb to rest on. 




Importantly, aluminum dovetail extrusions were used so that the platform and 
force transducer could be precisely positioned (Figure 8A). The force transducer was 
mounted on a carriage that rides on a dovetail that allows it to be positioned at an 
appropriate height (Figure 8B). The suture needed to be aligned so that it pulls on the 
lever of the transducer at a 90° angle so that the true muscle force could be measured. 
The micromanipulator to which the force platform is mounted to also rides along a 
dovetail so that it can be adjusted along the x-axis allowing us to align the suture with the 
force lever (Figure 8C & D).  
With these modifications, the Achilles IV has remained the final version of the 
force platform. Replicable in vivo force data is reliably obtained using this system. The 
R6/2 force-frequency data was collected again using this version of the platform. The 
final data will be presented in the following section of this thesis. First, we will discuss 
some of the advantages of 3D printing and its other applications with this system. We 
will also cover some additional considerations that had to be made during the design 







Figure 8: Achilles Positional Adjustment The Achilles platform and force transducer utilize aluminum 
dovetail extrusions for precise positional adjustment (A).  The force transducer is mounted to carriage 
that uses a dovetail extrusion that allows the transducer to be positioned at the proper height for force 
recordings (B). The micromanipulator (C) allows the platform to be positioned along the y-axis by being 
adjusted with fine movements with the turn of a dial. The dovetail the manipulator is mounted to allows 
the platform to also be moved along the x-axis so that the hind limb of the mouse can be aligned with 





3D MODELING AND PRINTING 
To design the Achilles platform before printing, it was first modeled using 
parametric modeling. The software used is called Fusion 360 from Autodesk. 
Conveniently, their software is free for students. Although it is free, it is a powerful 
software. We were able to create a 3D model of our force platform to its exact 
dimensions. Additionally, the companies that make many of the other components in our 
system have made the CAD files of their components available online. After the platform 
had been designed, we could model the entire system in the Fusion 360 environment 
(Figure 9). Fusion 360 also has the entire McMaster-Carr catalog with CAD models of 
their hardware. This was very helpful in determining all the small pieces of hardware we 
would need such as the various fasteners, washers, and inserts.  
The platform was modeled with the idea in mind that it would be mounted to a 
breadboard on the micromanipulator. We modeled mounting posts that can accept heat-
set threaded inserts. Once the part is printed, the inserts can be melted into place using a 
soldering iron. The inserts are knurled on the sides so that they create a strong bond with 
plastic as it cools. The platform can then be placed on the breadboard and fastened into 
place using metric hex screws. We also used this technique for fastening the metal straps 
for securing the ankle and foot in place on the platform. The straps we used were cut out 
of a sheet of stainless steel and were cut into shape using a rotary tool and cutoff wheel. 




Figure 9: Platform Modeling and 3D Printing The final version of the force platform, Achilles IV, was 
modeled using Fusion 360 from Autodesk. Many of the companies that make the various components in 
this system (Thorlabs, Newport, and Misumi) make the CAD files of their products available online. This 




Once the platform had been modeled, it is was time to print the parts. We decided 
to print the platform using fused deposition printing. The printer has a hot end that melts 
a plastic filament onto a heated print bed. It prints one small layer of the part at a time, 
each layer being 200 microns thick. For the printer to do this you have to generate code to 
instruct the stepper motors to move the hot end about the print bed and the filament 
through the extruder. We used a slicing software called Cura 4 from Ultimaker. The 
software slices the part into many 200-micron layers and generates the instructions the 
printer will use to print the part. An overview diagram of the printer is shown in figure 
10.  
The Achilles platform was printed using PETG (polyethylene terephthalate with a 
glycol modification) filament. There are many filaments available for 3D printing. Our 
two main choices were either PLA (polylactic acid) or PETG. PLA is one of the most 
widely available filaments. It is popular for hobbyist printers as it is very easy to print 
with, especially for beginners. However, it is made from plant starch. This makes it prone 
to warping from prolonged heat exposure. We needed a more heat-stable plastic since we 
are heating the bed during our experiments. PETG filament costs about the same as PLA 
filament but is more heat stable. It has the same ease of printing as PLA but has the 
durability of ABS. ABS is widely used in the manufacturing of consumer products that 
need to be very durable. However, ABS is harder to print with as it needs higher 




Figure 10: Diagram of 3D Printer The printer used to print the Achilles IV platform utilizes fused 
deposition modeling technology. The part is printed by a thermoplastic filament being melted through a 
hot end onto a heated print bed. The printer used in this project is a core XY printer. This means that the 
hot end moves along the X and Y-axis and the print bed moves along the Z axis. The hot end is on a 
carriage that moves along aluminum rails. Stepper motors move the hot end around the X and Y-axis 
using belts. There is also a cooling fan next to the hot end that cools the filament as it is extruded to the 
filament. Parts are printed in 200-micron layers until the entire part is printed. 
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Overall, printing our platform has been of great benefit. Not only for this 
application but also others around the lab. Now that our lab has the skills to model parts 
and print them, we can save significant costs on parts we would otherwise have to buy. 
The filament for the printer is very affordable. At the time of writing this, a kg of PETG 
is around twenty-five US dollars. Our force platform only takes about 200 g of filament. 
Therefore, we can print several platforms with one spool. Making and maintaining parts 
in the lab is cheap and easy. Also, once the parts are started on the printer the whole 
process is automated. One can leave and work on other things until the part is finished. 
As previously discussed, Achilles IV is the final version of the force platform. 
Achilles IV is a two-part platform. The base has a small cavity for Sylgard as well as 
some spaces for inserts on the top. On the bottom are the mounting posts for securing the 
platform to the breadboard. There is also a channel and some fasteners that allow the 
second part to adjust to different positions and be secured in place. The upper half of the 
platform is 20 mm thick and has a beveled edge to accommodate the upper leg and 
maintain the natural bend in the knee. It has a channel for Sylgard for the front paws to be 
pinned to. Once mounted on the breadboard and used in combination with our rail 
system, the Achilles IV keeps the mouse and its hind limb very stable. Our force 
recordings no longer show any shift in baseline after successive contractions. 
Additionally, tetanic muscle force no longer declines after repetitive tetani protocols, as 
the platform has been optimized to maintain maximal blood flow (Data not shown as it 
was performed after the completion of this thesis) 
According to our analysis, we were able to significantly improve the platform. 
Figure 11A shows that from Achilles II to Achilles IV the steady decline in resting 
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tension was dramatically reduced. The baseline from our first recording to the last during 
force-frequency experiments would drop by almost 50% when using Achilles II. We 
were able to reduce that to just over 15% with the Achilles IV platform (Figure 11B). 
Additionally, we saw a significant improvement in our twitch to tetanic ratio and 
achieved our goal ratio of 30% (Figure 11C).  
Figure 11: Assessment of Platform Improvement Early versions of the force platform produced force 
records that showed continual baseline decline throughout successive recordings. Achilles II showed 
significantly more baseline decline throughout force-frequency recordings than Achilles IV (A). Percent 
decline and twitch to tetanic ratio were both significantly decreases by the improvements made to 
Achilles IV (B). Significance assessed with Student’s t-test. Values are shown as ± SEM, n =  4 Achilles II 
& 4 Achilles IV. 
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IV. R6/2 FORCE-FREQUENCY DATA 
FORCE MEASUREMENT METHODS 
For force measurements, mice were anesthetized with isoflurane using a low-flow 
anesthesia system (SS-01, Kent Scientific, Torrington, CT), with body temperature 
maintained at ~35 ℃ using a heat lamp and temperature probe. The plantar flexor 
muscles (including the lateral and medial gastrocnemius, plantaris, and soleus muscles) 
and sciatic nerve were exposed by removing the surrounding skin. To minimize the 
influence of adjacent muscles, the common peroneal and tibial nerves were crushed. 
During surgery, the muscles were bathed in physiological saline to prevent them from 
drying out. The mice were then transferred to a custom platform filled with Sylgard and 
mounted to a micromanipulator (XR25/M, Thorlabs, Newton, NJ). The leg was stabilized 
to prevent movement. The proximal end of the plantar flexor muscles (Achilles tendon) 
was attached to the lever of the force transducer (300D-305C dual-mode muscle lever, 
Aurora Scientific, Ontario, Canada) using 5.0 or 6.0 silk suture and a modified Miller’s 
knot. The optimal length was obtained by measuring the maximum twitch force while 
lengthening the muscle using the micromanipulator.  
Nerve-evoked contractions were stimulated with platinum electrodes resting on the 
sciatic nerve. Direct muscle contractions were stimulated via platinum electrodes 
positioned above and below the plantar flexor muscles. Stimulus amplitude and the pulse 
width were determined by ensuring maximal twitch force was achieved. These values were 
typically ≤5 V at 1 ms or ≤50 V at 1.5 ms for nerve-stimulated and muscle-stimulated 
contractions, respectively. For muscle stimulated contractions ~150 µl α-bungarotoxin was 
injected intramuscularly. Nerve stimulated twitch force was assessed until it was reduced 
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to ≥25% of max. A Dagan S-900 Stimulator and S910 Stimulus Isolation Unit was used 
for stimulation. Muscle force was recorded and digitized using pClamp10 software 
(Molecular Devices, San Jose, CA). After each experiment, the muscles were quickly 
weighed and then frozen in isopentane cooled in liquid nitrogen. The muscles were stored 
in a –80 ℃ freezer until needed for further analysis. 
EXPERIMENTAL MICE 
 R6/2 mice were studied at end-stage HD and compared with age-matched 
littermates. Selection criteria were based on a combination of behavioral changes and 
weight loss based on daily checks after 10 weeks of age. Mice were taken once body weight 
loss reached 20% - 25% of max body weight. Animals are housed in the laboratory animal 
resources facility at Wright State University. They are kept in cage racks with littermates 
of the same sex. Once HD mice reach 10 weeks of age, they are given moist chow on the 
cage floor daily.   
STATISTICS 
A repeated measures ANOVA was run to compare WT vs HD muscle force at 
twitch force and 100 Hz. This was performed for both nerve and direct muscle stimulated 
force. The repeated measure accounts for potentially correlated results that can arise from 
the fact that it is the same mouse being measured at each of the two frequencies. SAS 
version 9.4 (SAS Institute, Inc., Cary, NC) was used for all analyses. Bonferonni multiple 
comparison procedure was used to control for a potentially inflated type I error rate 
(claiming a significant difference exists when it does not) that can result from making 
multiple comparisons. This procedure ensures that the type I error rate for the repeated 
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measures ANOVA is at most α = 0.05. Student’s t-tests were used where otherwise 
mentioned. 
FORCE-FREQUENCY DATA 
To complete specific aim 2, a force-frequency protocol was developed so that 
muscle force could be recorded at increasing frequencies. The protocol for each 
frequency featured a train of ten 1 ms pulses. Muscle force was recorded at a range of 
frequencies from 0.3-100 Hz. In all experiments, nerve stimulated contractions were 
performed first at all frequencies before moving to direct muscle stimulated contractions. 
Throughout all recordings, stimulus amplitude and pulse width were held constant. Once 
the platinum stimulating wires were placed on the sciatic nerve, the stimulus threshold 
was found by increasing the pulse amplitude until a twitch was generated. The stimulus 
was then increased by 20% to ensure that the stimulus remained above the threshold after 
multiple rounds of stimulation. The force platform was then adjusted using the 
micromanipulator so that optimal muscle length was reached. The optimal length was 
determined by stimulating a single twitch and then increasing the tension on the muscle 
by moving the platform 10 µm away from the force transducer and then stimulating 
another twitch. The peak force is assessed for each twitch while increasing resting muscle 
tension. This was repeated until the maximum twitch force was achieved. At this point, 
the muscle was rested for ten minutes before proceeding with force-frequency recordings. 
 A total of 6 WT and 4 HD mice were recorded. Peak force during the train was 
taken for each animal and then averaged for each genotype and data are presented as ± 
SEM. The average peak force for each frequency was added as a single point on the 
force-frequency graph. The points were then fit with a Boltzmann sigmoid curve 
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according to the following equation (𝑦𝑦 = 𝐴𝐴1−𝐴𝐴2
1+𝑒𝑒(𝑥𝑥−𝑥𝑥0)/𝑑𝑑𝑥𝑥
+ 𝐴𝐴2, 𝐴𝐴1 is the initial value and 
represents the bottom plateau of the curve, 𝐴𝐴2 is the final value and represents the upper 
plateau of the curve, 𝑥𝑥0 is the midpoint of the curve and represents the frequency of half 
max or f1/2max). Raw traces are shown for twitch and tetanic contractions (Figure 12A). 
As expected, as the stimulation frequency increases the force also increases due to 
summation. When looking at raw muscle force, our data is consistent with previous 
reports (Hering et al., 2006; Mielcarek et al., 2015). When compared to WT muscle force 
HD mice produce significantly less force at low and high frequencies (Figure 11B & C). 
However, at 30 Hz there is no significant difference between HD and WT raw force. This 
is likely due to the left shift in the force-frequency curve. As such, muscle force at 30 Hz 
is closer to maximum tetanic contraction for HD than for WT.  
Due to the known atrophy present in HD, it is important to normalize the muscle 
force to account for the difference in muscle size. To do this we normalized muscle force 
to muscle weight for each animal. Raw traces for specific force are shown in figure 12A. 
The normalized muscle force is called specific force. Looking at the specific force of the 
R6/2 muscle tells a completely different story than raw force. At all frequencies along the 
force-frequency curve, HD produces significantly more force than WT when normalized 
to muscle weight (Figure 12B & C). In the following section of this thesis, we will 
discuss some different possibilities as to why HD muscle is producing more force than 
WT muscle. This result was not expected. However, this has not yet been studied using 
the in vivo techniques presented here. The only other report on in vivo muscle force in the 




Figure 12: Raw Force-Frequency Data: Raw traces for twitch, 30 Hz, and 60 Hz are shown (A). Muscle 
force increases with stimulation frequency due to summation. WT muscle produces more force than 
HD at low and high frequencies (B). Twitch force and tetanic force at 100 Hz are significantly reduced 
in HD. Frequency of ½ max is significantly reduced in HD by 14 Hz compared to WT. All p-values > 
0.001, repeated measures ANOVA. Significance shown for frequency of ½ max using a Student’s t-
test. Values are shown as ± SEM, n = 6 WT & 4 HD (C).  
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contraction (Mielcarek et al., 2015). However, these results were not normalized and 
cannot be directly compared to our data. 
Muscle stimulated force was slightly lower than nerve stimulated force for both 
WT and HD as expected. It is very hard to get 100% of nerve stimulated force when 
stimulating the muscle directly. This is because the muscle is a very thick tissue 
compared to the nerve. It takes much less voltage to stimulate the entire nerve maximally.  
The direct muscle stimulated contractions also showed higher force than in HD 
than WT (Figure 13A). However, when looking at the muscle stimulated force-frequency 
curve for HD, a plateau can be noticed from 60 Hz on. In WT the force continues to 
climb. We hypothesize that HD muscle is more prone to fatigue. All the different 
Figure 13: Nerve Stimulated Specific Force-Frequency Raw traces of specific force are shown for twitch, 30 
Hz, and 60 Hz stimulation (A). When normalized to muscle weight, R6/2 muscle produces significantly more 
force at all frequencies throughout the force-frequency curve, p-value = 0.0032, repeated measures ANOVA 
(B & C). Values are shown as ± SEM, n = 6 WT & 4 HD. 
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frequencies were recorded one after another. We started at 0.3 Hz and worked through 
every frequency until we reached 100 Hz doing all nerve stimulated contraction before 
moving on to direct muscle stimulation. This means that by the time we started the 
muscle stimulated contractions we had stimulated ten trains. Once we started direct 
muscle stimulation and reached 60 Hz, we the muscle had endured 17 trains of 10 pulses 
each.  We believe that the cause of the dip in the muscle stimulated force curve in HD 
muscle is due to fatigue caused by the preceding trains.  
To test this, we compared the twitch to tetanic ratio of HD to WT for both nerve 
stimulated contractions and muscle stimulated contractions (Figure 14). We see that there 
is a significant difference in the twitch to tetanic ratio between HD and WT for direct 
Figure 14: Muscle Stimulated Force-Frequency To test for potential muscle fatigue due to repetitive 
stimulation the twitch to tetanic ratio was analyzed in nerve and muscle stimulated force (A). Twitch to 
tetanic ratio was significantly increased (Student’s t-test) in the HD muscle stimulated force-frequency 
curve. Due to this the muscle stimulated force-frequency curve plateaus at 60 Hz and beyond in HD (B). 
Values are shown as ± SEM, n = 6 WT & 4 HD. 
50 
 
muscle stimulated contractions but not for nerve stimulated contractions. Since the 
muscle was able to produce enough force to get a lower twitch to tetanic ratio when 
stimulated with the nerve, we believe that the muscle has been fatigued due to repeated 
stimulation.  
Finally, we noticed a different level of fusion between WT and HD tetanic 
contractions. As the frequency of stimulation increases, there is less time for the muscle 
to relax in between each stimulus. Therefore, a ten-pulse train at 40 Hz produces more 
force than a ten pule train at 20 Hz. This is known as summation. The level of fusion in 
each tetanus can be measured by finding the ratio of the antipeak to the peak. This is 
called the fusion index. A fusion index of one would be a fully fused tetanic contraction. 
We analyzed the fusion index for each frequency in both HD and WT. The fusion index 
in HD was significantly higher than WT (Figure 15).  
 
Figure 15: Fusion Index Fusion index was analyzed at 50 Hz which is near the middle of the force-
frequency curve. This is important because you need a partially fused tetanic contraction to assess the 
fusion index. Fusion index is a measure of the average Antipeak to the average peak (A). Each peak 
within the tetanus is averaged as well as the antipeak. Avg fusion index is shown for both HD and WT 





 Through the work described in this thesis, we have shown that peripheral defects 
are important to HD pathology. Our data suggest primary muscle defects may be a key 
component of the observed muscle defects in HD patients. It is clear that defects in the 
CNS are of importance as well to disease progression and symptomology. However, it is 
necessary to fully assess defects in all peripheral tissues, not just skeletal muscle. 
Furthermore, it is important to look at these defects rigorously and to assess if they are 
primary in nature. Peripheral defects would be the key to unlocking accessible targets for 
the treatment of HD.  
 The motor symptoms that occur in patients with HD are debilitating as the disease 
progresses. They eventually make it impossible for the affected individual to perform the 
simple activities of daily life that most take for granted. If the motor symptoms could be 
prolonged or tamed in some way, the quality of life and outlook for the patient would be 
greatly improved. Potentially, the life expectancy of those with HD could be increased as 
many patients die due to dysfunction in various muscles (muscles of mastication and 
swelling, as well as the heart, are most important).  
 The data presented here makes it clear that there are indeed muscle defects in 
R6/2 skeletal muscle function. These defects need to be further explored as we have not 
determined the precise mechanism underlying these defects. However, in the following 
sections, we will discuss some possible physiological mechanisms that could be altered 





 Our lab previously assessed neurotransmission in R6/2 mice and found altered 
neurotransmission including reduced quantal content and both spontaneous and evoked 
endplate potentials (Khedraki et al., 2017). This was shown to be due to a reduced 
probability of release of vesicles in the nerve terminal. This data is what led us to 
hypothesize that muscle force would be reduced in R6/2 muscle. We observed increased 
specific force in response to both nerve and direct muscle stimulated contractions. 
Therefore, it is unlikely that altered neurotransmission is impacting muscle force at least 
during the brief stimulations that are performed to collect the force-frequency data. If 
altered neurotransmission were altering the muscle force, we would expect to see the 
reduced specific force with nerve stimulation but not when stimulating the muscle -/-
directly after application of BTX.  
 Recently, we published a paper using the force platform that was developed in 
this thesis. In this paper, it was shown using BK-/- mice that the absence of BK (big 
conductance potassium) channels in the nerve terminal alters neurotransmission (Wang et 
al., 2020). This work highlights how our technique can show nerve defects in muscle 
force recordings. Nerve stimulated force, in this case, was significantly reduced in BK-/- 






Figure 16: Reduction in Muscle Force Caused by Altered Neurotransmission Shown here is an example of 
how the Achilles IV was put to use to find the cause of muscle weakness in mice lacking big conductance 
K+ (BK) channels. (A) Representative specific force traces from wild type (black) and BK–/– (red) muscle 
showing twitches (top panel) and responses to 30 Hz (middle panel) and 60 Hz (bottom panel) stimulation 
for both nerve stimulation (left column) and direct muscle stimulation (right column). (B) Bar graph 
showing twitch specific force for nerve and muscle stimulation. Values shown as mean ± SEM, * indicates 
a p-value < 0.05, one-way ANOVA. (C) Specific force-frequency curves, fitted with a Boltzmann equation, 
for WT nerve (black solid line) and muscle (black dashed line) stimulation as well as BK–/– nerve (red 





CONTRACTILE MACHINERY MODIFICATIONS 
 Contractile filament alteration could play a role in the increased specific force in 
R6/2 muscle. Regulatory proteins are present in both myosin and actin and different 
isoforms and levels of expression for both have been shown (Bozzo et al., 2003; Gordon 
et al., 2000; Schiaffino and Reggiani, 1996).  Myosin light chain (MyLC) 
phosphorylation alters contractile filament sensitivity to [Ca2+]i (Schoffstall et al., 2006). 
When MyLC is phosphorylated, the binding affinity for Ca2+ is increased and force 
production is increased (Bozzo et al., 2005). 
 A complete review of all these contractile filament regulatory proteins as well as 
their transcriptional modifications is beyond the scope of this thesis. However, 
remodeling of contractile filaments and regulatory proteins could be affecting R6/2 force 
production. Mutant Htt is known to interact with intracellular proteins and alter gene 
expression. These protein interactions still need to be explored, especially in skeletal 
muscle. 
ALTERED INTRACELLULAR CALCIUM HOMEOSTASIS 
 The proper transport and handling of [Ca2+]i is very important for muscle 
contraction in response to APs. We have talked about the release of Ca2+ through the 
opening of ryanodine receptors in the SR membrane. Previous reports have shown no 
change in the expression of ryanodine receptors in R6/2 muscle (Braubach et al., 2014). 
Additionally, the SERCA pump responsible for pumping Ca2+ back into the SR should 
also be considered. Increased Ca2+ or decreased SERCA pumps or activity could result in 
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elevated [Ca2+]i. Braubach et al. assessed both and found decreased Ca2+ release with 
decreased Ca2+ reuptake into the SR. They did not assess SERCA pump expression. 
Interestingly, they also found increased Ca2+ entry from the extracellular space.  
 Our fusion index data suggest some change in Ca2+ handling during muscle 
contraction. Additionally, a leftward shift in the force-frequency curve could be partially 
explained by altered Ca2+ handling. Fusion occurs when Ca2+ is not completely pumped 
back into the SR when the next stimulus of a train causes the ryanodine receptors to open 
again. This gives less time for the force to return to baseline before climbing again in 
response to the stimulus. If there is increased [Ca2+]i during muscle contraction in R6/2 
mice, then more force could be produced at a given frequency than in WT muscle causing 
a leftward shift in the force-frequency curve. 
MUSCLE FATIGUE DUE TO REPETITIVE STIMULATION  
 Rarely in biological research does an observed change in physiology happen in 
isolation. Increased force output, on one hand, could be viewed as being advantageous, 
but on the other hand, it will likely come at a cost. The direct muscle stimulated force-
frequency curve would suggest that this is the case. In R6/2 muscle the force-frequency 
curve plateaus at frequencies above 60 Hz, whereas the WT force curve continues to 
climb. We believe that we caused the R6/2 muscle to fatigue due to the repeated 
stimulation that was performed to collect the data needed for two force-frequency curves 
in succession.  
 The twitch to tetanic data supports this notion. The twitch to tetanic ratio for the 
nerve stimulated curve in R6/2 muscle was not significantly different than WT. We were 
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able to obtain a ratio of around 30% for both R6/2 and WT during nerve stimulation. 
However, the twitch to the tetanic ratio for the muscle stimulated curve in R6/2 was 
significantly different from WT. Near the end of our experiment R6/2 muscle was 
producing less tetanic force than it was earlier when we were stimulating the nerve.  
 Increased muscle weakness after prolonged activity fits with patient 
symptomology. Patients suffer from motor impersistence (Paulson and Albin, 2011) 
which is the inability to sustain a voluntary muscular effort. They also suffer from chorea 
which results in irregular and jerky movements. R6/2 muscle being hyperexcitable 
(Waters et al., 2013) and producing more force while being more prone to fatigue could 
help explain some of these symptoms.  
 It would be important to perform further studies to assess muscle fatigue in R6/2 
muscle. A protocol including repeated rounds of tetanic stimulation could be developed 
and used to characterize the level of fatigue in response to sustained activity in R6/2 
muscle. This type of stimulation protocol better mimics activities such as locomotion. 
The brief stimuli of twitches and the short trains used in this study are not as relevant 
physiologically to sustained activity which is important for tasks such as coordinated 








 Upon successful development of the Achilles in vivo muscle force system, R6/2 
muscle function was able to be assessed by generating force-frequency curves. We found 
that raw muscle force in the R6/2 mouse model of HD is reduced when compared to WT 
littermates. This data is consistent with previous reports (Hering et al., 2006; Mielcarek et 
al., 2015). However, when normalized to muscle weight, specific force produced by R6/2 
mice is significantly higher than WT. Additionally, increased fusion index suggests that 
altered myocyte Ca2+ homeostasis could be causing increased specific force in R6/2 
muscle. Defects in myocyte Ca2+ homeostasis have been shown in the R6/2 line 
(Braubach et al., 2014). Future research must be conducted to determine the specific 
mechanisms that are responsible for the altered Ca2+ handling during muscle contraction. 
 Muscle fatigue was detected in the direct muscle stimulated force-frequency data. 
The twitch to tetanic ratio was significantly increased in R6/2 muscle suggesting that the 
plantar flexor muscles were fatigued due to repeated stimulation. Since nerve stimulated 
contractions were performed prior to direct muscle stimulation, the muscle had contracted 
over fifteen times at different frequencies. WT muscle had no problem with this level of 
stimulation and the twitch to tetanic ratio was consistent from nerve stimulation to 
muscle stimulation in WT muscle. To further assess how prone to fatigue HD muscle is, 
repeated stimulation protocols should be developed, and muscle force should be assessed. 
 With motor dysfunction being the primary symptom of HD and a leading cause of 
mortality, skeletal muscle defects are a promising target for the treatment of symptoms in 
HD. This work provides additional support for the continued study of primary peripheral 
defects in animal models of HD. There is no doubt that cognitive decline and striatal 
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degeneration also play a key role in the progression of HD symptoms, but unfortunately 
these areas are harder to treat. Even if symptoms could be partially ameliorated and 
progression of the disease slowed by some percentage, patient outlook could be 
drastically improved. 
 An essential tool for the development of the muscle force system used to 
complete this thesis was the ability to rapidly create various prototypes by utilizing 3D 
modeling and printing. There is no doubt that the skills obtained throughout this project 
will be used in future endeavors. It is our hope that 3D printing will continue to be 
utilized in biological research. Here, we have only scratched the surface of the potential 
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